肾性贫血治疗的进展

Progress In the Treatment of Renal Anemia

促红细胞生成素(EPO)的相对或者绝对不足和铁缺乏是肾性贫血的主要原因。重组人促红细胞生成素(rHuEPO)是治疗肾性贫血的有效药物。近年来多个大型研究显示使用高剂量rHuEPO是引起血液透析患者死亡率增加的独立危险因素。低氧刺激因子-脯氨酰羟化酶抑制剂(HIF-PHI)可通过稳定缺氧刺激因子(HIF),促进EPO的合成和铁的利用,成为具有临床应用前景的新一类治疗肾性贫血的药物。

The relative or absolute deficiency of erythropoietin (EPO) and iron deficiency are the main causes of renal anemia. Recombinant human erythropoietin (rHuEPO) is an effective drug for the treatment of renal anemia. Recently, several large studies have shown that the use of highdose rHuEPO is an independent risk factor for mortality in hemodialysis patients. HIF prolyl hydroxylase inhibitors (HIF-PHI) can promote the synthesis of EPO and the use of iron by stabilizing the hypoxia stimulating factor (HIF), and become a new drug for the treatment of renal anemia with clinical application.